SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001193125-23-027748
Filing Date
2023-02-08
Accepted
2023-02-08 09:13:30
Documents
13

Document Format Files

Seq Description Document Type Size
1 424B3 d429998d424b3.htm 424B3 1814936
2 GRAPHIC g429998g01a77.jpg GRAPHIC 678230
3 GRAPHIC g429998g01a78.jpg GRAPHIC 644268
4 GRAPHIC g429998g01a79.jpg GRAPHIC 621199
5 GRAPHIC g429998g01a80.jpg GRAPHIC 660640
6 GRAPHIC g429998g01a81.jpg GRAPHIC 627155
7 GRAPHIC g429998g01a82.jpg GRAPHIC 655382
8 GRAPHIC g429998g01a83.jpg GRAPHIC 718049
9 GRAPHIC g429998g01a87.jpg GRAPHIC 630812
10 GRAPHIC g429998g01a88.jpg GRAPHIC 739090
11 GRAPHIC g429998g01a90.jpg GRAPHIC 612231
12 GRAPHIC g429998g02b88.jpg GRAPHIC 607289
13 GRAPHIC g429998g73m62.jpg GRAPHIC 49454
  Complete submission text file 0001193125-23-027748.txt   11690896
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-269521 | Film No.: 23597286
SIC: 2836 Biological Products, (No Diagnostic Substances)